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Management of cardiac hemochromatosis
Wilbert S. Aronow
A b s t r a c t
Iron-overload syndromes may be hereditary or acquired. Patients may be 
asymptomatic early in the disease. Once heart failure develops, there is 
rapid deterioration. Cardiac hemochromatosis is characterized by a  dilat-
ed cardiomyopathy with dilated ventricles, reduced ejection fraction, and 
reduced fractional shortening. Deposition of iron may occur in the entire 
cardiac conduction system, especially the atrioventricular node. Cardiac he-
mochromatosis should be considered in any patient with unexplained heart 
failure. Screening for systemic iron overload with serum ferritin and trans-
ferin saturation should be performed. If these tests are consistent with iron 
overload, further noninvasive and histologic confirmation is indicated to 
confirm organ involvement with iron overload. Cardiac magnetic resonance 
imaging is superior to other diagnostic tests since it can quantitatively as-
sess myocardial iron load. Therapeutic phlebotomy is the therapy of choice 
in nonanemic patients with cardiac hemochromatosis. Therapeutic phlebot-
omy should be started in men with serum ferritin levels of 300 µg/l or more 
and in women with serum ferritin levels of 200 µg/l or more. Therapeutic 
phlebotomy consists of removing 1 unit of blood (450 to 500 ml) weekly 
until the serum ferritin level is 10 to 20 µg/l and maintenance of the serum 
ferritin level at 50 µg/l or lower thereafter by periodic removal of blood. 
Phlebotomy is not a  treatment option in patients with anemia (secondary 
iron-overload disorders) nor in patients with severe congestive heart failure. 
In these patients, the treatment of choice is iron chelation therapy.
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Introduction
Hemochromatosis is caused by abnormal deposition of iron in paren-
chymal organs causing organ toxicity and dysfunction. Cardiac hemo-
chromatosis or primary iron-overload cardiomyopathy is an important 
and potentially preventable cause of heart failure. Iron-overload syn-
dromes may be hereditary or acquired. There are 4 subtypes of heredi-
tary hemochromatosis resulting from increased gastrointestinal absorp-
tion of iron into the bloodstream. Reduced activity or reduced synthesis 
of hepcidin.cause most cases of hemochromatosis. The 4 subtypes are 
type 1 caused by the high iron (HFE) gene which accounts for more than 
80% of hemochromatosis cases, type 2 caused by the hemojuvelin gene, 
type 3 caused by the transferrin receptor-2 gene, and type 4 caused by 
the ferroportin gene. Iron overload cardiomyopathy is defined as systolic 
or diastolic cardiac dysfunction caused by increased deposition of iron 
and emerging as an important cause of congestive heart failure because 
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of the increased incidence of this disorder seen 
in thalassemic patients and in patients with he-
reditary hemochromatosis [1]. Cardiomyocyte fer-
oportin regulates cellular iron homeostasis, and 
the site of myocardial iron deposition determines 
the severity with which cardiac function is affect-
ed [2]. The prevalence of hemochromatosis in the 
United States of America is 0.37%. Thalassemia 
is an example of a  hereditary anemia requiring 
frequent blood transfusions. Thalassemia occurs 
in 4.4 of every 10,000 live births throughout the 
world. Alpha-thalassemia is most common among 
persons of Southeast Asian descent. Beta-thal-
assemia is most common among populations of 
Mediterranea, African, and South Asian ancestry. 
Clinical features
Patients may be asymptomatic early in the dis-
ease. Once heart failure develops, there is rapid 
deterioration. Cardiac hemochromatosis causes 
a dilated cardiomyopathy with dilated ventricles, 
low left ventricular ejection fraction (LVEF), and 
decreased fractional shortening [3, 4]. Patients 
may have exertional dyspnea caused by left ven-
tricular diastolic dysfunction with restrictive he-
modynamics and increased filling pressures. Di-
lated cardiomyopathy with a low LVEF develops as 
the disease progresses. Biventricular failure caus-
es pulmonary congestion, peripheral edema, and 
hepatic congestion [5]. Pericardial constriction or 
tamponade caused by pericardial iron deposition 
may result in rapid clinical deterioration [6]. An-
gina pectoris without coronary artery disease re-
sponding to venesection may also occur [7]. 
Deposition of iron may occur in the entire cardi-
ac conduction system, especially the atrioventric-
ular node. Complete atrioventricular block caused 
by iron depostion may need implacement of 
a permanent pacemaker [8]. Iron deposition in the 
cardiac tissue causes nonhomogenous electrical 
conduction and repolarization with atrial and ven-
tricular tachyarrhythmias [9]. Chronic iron over-
load reduces CaV1.3-dependent L-type Ca2+ cur-
rents, resulting in bradycardia, altered electrical 
conduction, and atrial fibrillation [10]. Paroxysmal 
atrial fibrillation is the most common arrhythmia 
observed in patients with cardiac hemochromato-
sis. The prevalence of ventricular arrhythmias in-
creases with left ventricular dilation and low LVEF. 
Sudden cardiac death may develop [11]. Cardiac 
hemochromatosis is not associated with ischemic 
heart disease or myocardial infarction [12, 13].
Diagnosis
Biochemical measures 
Cardiac hemochromatosis should be consid-
ered in any patient who has unexplained heart 
failure. Screening for systemic iron overload with 
serum ferritin and transferin saturation should be 
performed. If the results of these tests are consis-
tent with iron overload, further noninvasive and 
histologic confirmation is indicated to confirm or-
gan involvement with iron overload.
Guidelines recommend that a plasma transferin 
saturation exceeding 55% and a serum ferritin ex-
ceeding 200 ng/ml in women or exceeding 300 ng/ 
ml in men identify patients with iron overload 
[14, 15]. Since serum ferritin is an acute phase 
reactant, it is unreliable in disorders with active 
inflammation [16]. Serum iron studies are useful 
for screening for total body iron overload but are 
unreliable for diagnosing organ-specific overload 
such as cardiac iron. Serum ferritin levels do not 
correlate with the severity of myocardial iron over-
load. High myocardial iron deposition may occur 
despite low serum ferritin levels [17]. There is 
a strong association between plasma N-terminal 
pro-B-type natriuretic peptide levels and indices 
of iron overload [18].
Biopsy of tissues
Liver biopsy is the best biopsy to quantify iron 
overload. However, there is no correlation be-
tween liver and myocardial iron deposition. Myo-
cardial iron deposition is slower than uptake of 
iron by the liver. Endomyocardial biopsy may have 
to be performed in patients with cardiac mani-
festations. Myocardial iron is consistently found 
in endomyocardial biopsy specimens in patients 
with left ventricular dysfunction resulting from 
cardiac hemochromatosis.
Electrocardiographic findings
The electrocardiogram (ECG) is usually nondi-
agnostic in early cardiac hemochromatosis. With 
advanced cardiac hemochromatosis, low QRS 
complex voltage and nonspecific ST and T wave 
abnormalities are present on the ECG. Atrial tach-
yarrhythmias, especially paroxysmal atrial fibrilla-
tion, are common. Ventricular arrhythmias occur if 
there is a reduced LVEF. Iron deposition in the con-
duction system may cause first-degree, second-de-
gree, and complete atrioventricular block [8].
Echocardiographic findings
Left ventricular diastolic dysfunction secondary 
to a restrictive physiology is seen early in cardiac 
hemochromatosis and can be diagnosed by echo-
cardiography. This will progress to a  dilated car-
diomyopathy with a  reduced LVEF. Patients with 
cardiac hemochromatosis may have left and right 
cardiac chamber dilatation and a low LVEF or left 
atrial and right ventricular dilatation with increased 
pulmonary artery pressure and a normal LVEF [19]. 
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Eccentric left ventricular hypertrophy may also oc-
cur [20]. Tissue Doppler echocardiography may be 
used to diagnose left ventricular diastolic dysfunc-
tion early in cardiac hemochromatosis [21].
Cardiac magnetic resonance imaging findings
Although echocardiography may be used to 
screen for myocardial iron overload, it does not 
accurately predict myocardial iron content. Cardi-
ac magnetic resonance (CMR) imaging can quan-
titatively assess myocardial iron load. In patients 
with cardiac hemochromatosis, the iron overload-
ed myocardium shows changes in signal intensity 
and susceptibility with a  shorter relaxation time 
and quicker darkening of the image caused by 
the paramagnetic effect of iron [22]. The relax-
ation time may be measured using the spin echo 
technique, where the signals are refocused using 
a  special radiofrequency pulse, or by using the 
small magnetic fields called gradients (gradient 
echo) at specific time intervals called echo time. 
The time constant of decay for the relaxation 
time is inversely proportional to the myocardial 
iron content. The greater the iron content in the 
myocardium, the shorter are the T2 and T2*, the 
time constant of decay for spin echo and gradient 
echo-induced relaxation time, respectively. Spin 
echo is less sensitive than gradient echo for as-
sessing the iron content in the myocardium [23]. 
The T2* method is more sensitive and highly spe-
cific for quantitation and longitudinal tracking of 
myocardial iron deposition. There is good inverse 
correlation between the patient’s myocardial T2* 
and LVEF and significant correlation between the 
patient’s myocardial T2* and the need for therapy 
of the cardiac hemochromatosis [24].
T2* relaxation time is determined by iron in the 
form of hemosiderin and not by iron in the form 
of labile cellular iron or ferritin and accurately 
predicts myocardial iron content [25]. The clinical 
severity of myocardial iron overload in cardiac he-
mochromatosis is assessed by T2* values. Patients 
with a T2* relaxation time greater than 20 ms are 
at low risk for developing congestive heart fail-
ure. Patients with a T2* relaxation time between 
10 and 20 ms probably have depostion of iron in 
their myocardium and are at intermediate risk for 
developing congestive heart failure. Patients with 
a  T2* relaxation time of less than 10 ms are at 
high risk for developing congestive heart failure 
and need chelation therapy [26]. In a prospective 
study of 662 thalassemia major patients, conges-
tive heart failure developed within 1 year in 47% 
of patients with a  T2* relaxation time less than 
6 ms, in 21% of patients with a T2* relaxation time 
of 6 to 10 ms, and in 0.2% of patients with a T2* 
relaxation time greater than 10 ms [25]. Cardiac 
arrhythmias developed within 1 year in 19% of 
patients with a T2* relaxation time less than 6 ms, 
in 18% of patients with a T2* relaxation time of 
6 to 10 ms, and in 4% of patients with a T2* relax-
ation time greater than 10 ms [27].
In addition to quantifying the myocardial iron 
load in patients with cardiac hemochromatosis, 
CMR imaging can assess stress-induced myocar-
dial ischemia, myocardial viability, resting LVEF, 
left ventricular end-systolic and end-diastolic vol-
umes, and left ventricular mass. A  reduction in 
LVEF correlates with the myocardial iron content 
measured by T2* relaxation time [28]. When the 
T2* relaxation time is below 20 ms, left ventricular 
systolic function decreases progressively, accom-
panied by increased left ventricular end-systolic 
volume and increased left ventricular mass [29].
Approach to diagnosis of hemochromatosis
Hemochromatosis may be suspected by a pos-
itive family history, abnormal hepatic enzymes, 
endocrinopathies, or other organ systems involve-
ment. A  thorough history and physical examina-
tion should be obtained. Patients suspected of 
having hemochromatosis should have measure-
ments of transferrin saturation and ferritin for di-
agnosis of iron overload and assessment of other 
organ involvement such as liver, pancreas, thyroid, 
and gonads. Genetic testing should be performed 
to diagnose hereditary hemochromatosis. An ECG 
and chest roentgenogram should be obtained [30].
Patients without cardiac symptoms suspected 
of having hemochromatosis should have a trans-
thoracic echocardiogram with assessment of left 
ventricular diastolic function including tissue Dop-
pler imaging measurements of the mitral annu-
lus every 1 to 2 years [31]. If there is abnormal 
left ventricular diastolic function and/or reduced 
peak systolic tissue velocity of the mitral annulus 
detected by echocardiography, CMR with T2* re-
laxation time measurement should be obtained. 
Periodic evaluation of ventricular function may 
help uptitration of medical treatment for heart 
failure and decide if an implantable cardiovert-
er-defibrillator is indicated. Echocardiography 
should be performed every 6 to 12 months if the 
T2* relaxation time measured by CMR is less than 
20 ms and every 6 months or less if the patient 
becomes symptomatic. The CMR with measure-
ment of T2* relaxation time should be performed 
in all patients with idiopathic cardiomyopathy. 
A normal serum iron measurement does not rule 
out myocardial iron overload in patients with he-
mochromatosis. Therapy of cardiac hemochroma-
tosis should be guided by abnormal CMR results. 
The CMR is an excellent tool for early diagnosis 
of heart involvement, risk stratification, treatment 
evaluation, and long-term follow-up of patients 
with metabolic cardiomyopathies including cardi-
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ac hemochromatosis [32]. Patients who have an 
endomyocardial biopsy for heart failure caused 
by a dilated cardiomyopathy of unknown etiology 
should have iron staining of the biopsy specimens 
since stainable iron is consistently observed in pa-
tients with cardiac hemochromatosis and reduced 
left ventricular systolic function [33, 34]. Patients 
suspected of having hemochromatosis should be 
investigated for evidence of myocardial iron depo-
sition with treatment started immediately if cardi-
ac hemochromatosis is diagnosed.
Therapy
Therapy of iron-overload states is important to 
prevent or reverse cardiac dysfunction [35–39]. 
Removal of excess iron from the tissues in these 
patients minimizes generation of free radicals, re-
ducing organ damage [40, 41]. Therapy to remove 
excess iron stores includes therapeutic phlebotomy 
and iron-chelating agents. Therapy of the primary 
disease causing iron overload and dietary man-
agement are also important in managing cardiac 
hemochromatosis. Dietary management includes 
avoidance of medicinal iron, mineral supplements, 
excess vitamin C, and uncooked seafoods [39]. 
Congestive heart failure should be managed with 
standard medical therapy for heart failure [42]. 
Therapeutic phlebotomy for cardiac 
hemochromatosis
Therapeutic phlebotomy is the therapy of 
choice in nonanemic patients with cardiac hemo-
chromatosis. Therapeutic phlebotomy should be 
started in men with serum ferritin levels of 300 
µg/l or more and in women with serum ferritin lev-
els of 200 µg/l or more, regardless of the presence 
or absence of symptoms [39]. Therapeutic phle-
botomy consists of removing 1 unit of blood (450 
to 500 ml) weekly until the serum ferritin level is 
10 to 20 µg/l and maintenance of the serum ferri-
tin level at 50 µg/l or lower thereafter by periodic 
removal of blood [39]. Each unit of blood removed 
depletes 200 to 250 mg of iron from the blood. 
This removal of iron from the blood mobilizes an 
equal amount of iron stored in the tissues to form 
hemoglobin [43]. Patients with ferroportin muta-
tion-associated iron overload may not tolerate 
a more aggressive schedule [44]. Serum ferritin is 
measured every month until it reaches 200 ng/ml 
and once in 1 to 2 weeks after. Measurement of 
hemoglobin and hematocrit should be obtained 
before each phlebotomy. Phlebotomy should not 
be not performed if the hematocrit falls below 
80% of the previous value [45]. After reaching 
a target ferritin level below 50 ng/ml and transfer-
rin saturation below 30%, the frequency of phle-
botomy is reduced. The frequency of maintenance 
phlebotomy varies once every few months to few 
years depending on the iron reaccumulation rate 
[46]. Adequate hydration is recommended before 
and after phlebotomy to prevent volume deple-
tion. Phlebotomy lowers the myocardial iron con-
tent and improves left ventricular diameter, left 
ventricular fractional shortening, LVEF, left ven-
tricular mass, and left atrial dimension in these 
patients [47–49]. 
Therapeutic phlebotomy performed before iron 
overload becomes severe prevents complications 
caused by iron overload such as hepatic crrhosis, 
primary hepatic carcinoma, diabetes mellitus, hy-
pogonadotrophic hypogonadism, joint disease, 
and cardiomyopathy [39]. Patients with these 
complications often need additional specific man-
agement [39]. Medical therapy to treat congestive 
heart failure from cardiomyopathy and serious 
cardiac arrhythmias in patients with cardiac he-
mochromatosis must be used until therapeutic 
phlebotomy possibly combined with iron chela-
tion therapy reduces the excess myocardial iron 
content [39].
Iron chelation treatment
Phlebotomy is not an option for therapy in 
patients with anemia (secondary iron-overload 
disorders) nor in patients with severe heart fail-
ure [50]. In these patients, the therapy of choice 
is iron chelation treatment [51]. Iron chelating 
agents increase the iron excretion rate by bind-
ing to the iron in plasma and tissues, depleting 
the body of excess iron [52]. Serum ferritin levels 
should be periodically obtained. When the serum 
ferrtin level falls below 1000 ng/ml, iron chelation 
therapy should not be given [53]. Deferoxamine, 
deferiprone, and deferasirox are the 3 iron-chelat-
ing drugs approved by the United States Food and 
Drug administration for management of chronic 
secondary iron overload.
Deferoxamine is a hexadentate molecule which 
binds directly to labile iron in plasma and in tis-
sues including the heart [54]. Deferoxamine has 
poor oral bioavailability and a short half-life. This 
drug is administered as a subcutaneous or intra-
venous infusion. The recommended dose in adults 
is 40 to 50 mg/kg/day infused over 8 to 12 h for 
5 to 7 days per week. Treatment with deferoxamine 
therapy reduces myocardial iron content approx-
imately 24%, delays onset of cardiac hemochro-
matosis, reverses early cardiac hemochromatosis, 
improves left ventricular function, and improves 
survival in transfusion-dependent patients who 
have thalassemia [55–58]. However, long-term 
compliance with deferoxamine is poor [59].
Deferiprone is an orally active bidentate iron 
chelator approved for management of iron over-
load in transfusion-dependent patients with 
thalassemia when current chelation treatment is 
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not adequate. The starting dose of deferiprone is 
75 mg/kg/day administered in 3 divided doses. 
The maximum dose of deferiprone is 99 mg/kg/
day. Some studies have found that deferiprone is 
better than deferoxamine in lowering myocardial 
iron content [60, 61]. Combination treatment with 
deferiprone plus deferoxamine has been found to 
rapidly lower iron overload and improve cardiac 
function in iron overload patients with heart fail-
ure and unstable hemodynamics [62–64].
Deferasirox is a tridentate iron chelating drug 
with good oral bioavailability approved to man-
age iron overload resulting from recurrent blood 
transfusions. The initial oral dose of deferasirox 
given once daily is 20 mg/kg/day which can be 
increased to a maximum dose of 40 mg/kg/day 
[65]. Deferasirox lowers the serum ferritin level 
and lowers iron overload of the heart and liver 
[66–70]. Newer iron-chelating agents being in-
vesigated for the therapy of chronic iron overload 
disorders include silybin [71], deferitrin [72], and 
starch conjugated deferoxamine [73]. Percutane-
ous excretion of iron and ferritin through Al-hi-
jamah is a  novel treatment for iron overload in 
β-thalassemia major, hemochromatosis, and sid-
eroblastic anemia [74].
Dietary treatment
Iron supplements should not be ingested [39]. 
Eating large amounts of vitamin C rapidly mobi-
lizes iron from the heart, increases free radicals 
production, and causes fatal cardiac arrhythmias 
[75, 76]. Therefore, supplemental vitamin C should 
not be ingested by these patients. However, veg-
etables and fruits rich in vitamin C may be eaten 
[77]. Alcohol increases iron absorption, and some 
red wines contain a high iron content [78, 79]. Pa-
tients with hereditary hemochromatosis should 
avoid eating raw shellfish [79]. Patients with car-
diomyopathy and heart failure should be treated 
with a low sodium diet [42]. 
Erythrocytapharesis in hemochromatosis
Erythrocytapharesis is the technique of selec-
tive removal of red blood cells, with or without 
administering erythopoietin [80, 81]. This pro-
cess removes excess iron stores from the tissues 
twice as rapidly as phlebotomy of whole blood 
[82]. In a  study of patients with hereditary he-
mochromatosis, therapeutic erythrocytapheresis 
showed almost a 70% decrease in the total num-
ber and the duration of treatments compared 
with phlebotomy [83]. End-stage cardiomyopa-
thy caused by hereditary hemochromatosis was 
successfully treated with erythrocytapheresis in 
combination with left ventricular assist device 
support [84]. 
Cardiac transplantation for cardiac 
hemochromatosis
Cardiac transplantation is a therapeutic option 
for patients with cardiac hemochromatosis with 
severe heart failure refractory to optimal medi-
cal therapy and cardiac resynchronization thera-
py [42, 48, 85]. Of 16 patients who had cardiac 
transplantation for iron overload cardiomyopathy, 
the etiology was primary hemochromatosis in 
11 patients, thalassemia major in 4 patients, and 
Diamond-Blackfan anemia in 1 patient [86]. The 
30-day mortality was 12%, with the 3 deaths due 
to infectious complications [86]. The actuarial Ka-
plan-Meier survival rates at 1, 3, and 5 years were 
81%, 81%, and 81%, respectively [86]. The actuar-
ial survival at 10 years was 41% [86]. 
Congestive heart failure after liver transplanta-
tion may require a biventricular assist device [87]. 
Combined heart-liver transplantation is indicated 
in patients with severe iron overload cardiomy-
opathy and cirrhosis [88]. All of these patients 
should continue to have therapy to decrease iron 
overload to prevent hemochromatosis of the 
transplanted heart [89]. In patients with second-
ary iron overload such as the myelodysplastic syn-
drome [90], sickle cell anemia [91], β-thalassemia 
[92], and the Diamond-Blackfan syndrome [93], 
hematopoietic stem cell transplantation can re-
duce requirements for blood transfusion and slow 
the rate of iron overload in these patients.
Therapies under investigation for 
hemochromatosis
Calcium channel blockers
L-type Ca2+ channels and T-type calcium chan-
nels provide a major pathway for iron entry into car-
diomyocytes in iron overload cardiomyopathy [94–
96]. Amlodipine has been demonstrated to reduce 
iron uptake and oxygen free radical production in 
the heart of chronically iron overloaded mice [97]. 
Therapy with calcium channel blockers (nifedipine, 
verapamil, and efonidipine) and a divalent metal 
transporter1 (ebselen) have shown a decrease in 
cardiac iron deposition, cardiac malondialdehyde, 
and plasma non-transferrin-bound iron and an 
improvement in heart rate variability and in left 
ventricular function in thalassemic mice with iron 
overload [98]. Efonidipine and ebselen reduced 
mortality in these mice [98]. Further investigation 
is needed to determine whether calcium channel 
blockers can be efficacious in the prevention and 
treatment of iron overload cardiomyopathy.
Hepcidin therapy
Deficiency of hepcidin, the hormone that con-
trols iron absorption and its distribution in tissues, 
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is the cause of iron overload in nearly all forms of 
hereditary hemochromatosis and in untransfused 
iron loading anemias [99–104]. Hepicidin analogs 
have been demonstrated to reduce iron overload 
and excess iron-induced tissue toxicity in mouse 
models [99, 101]. Minihepcidins are smaller hep-
cidin-like peptides which have been shown to re-
duce myocardial iron content in hepcidin knockout 
mice [104]. Minihepcidins prevented iron overload 
in a hepcidin-deficient mouse model of severe he-
mochromatosis [104]. Minihepicidins could possi-
bly be beneficial in iron overload disorders either 
used alone for prevention or as adjunctive therapy 
with phlebotomy or chelation [104]. Natural hepci-
din and hepcidin analogs are under investigation 
to treat iron overload in hemochromatosis. 
Apotransferrin treatment reduced erythroid 
Fam132b gene (erythroferrone) expression, in-
creased hepatic hepcidin gene expression and 
plasma hepcidin-25 levels, and reduced intestinal 
ferroportin-1 in apotransferrin-treated thalas-
semic mice [105]. Apotransferrin treatment needs 
further investigation for normalizing iron content 
in the myocardium and other organs. 
Gene therapy
Management of underlying disorders such as 
β-thalassemia and sickle cell disease by gene 
therapy may prevent need for blood transfusions 
and prevent iron overload in tissues [106, 107]. 
Targets for gene therapy have been recommend-
ed for patients with hereditary hemochromatosis 
including inhibition of divalent metal transport-
er1 and ferroportin gene expression in entero-
cytes [108]. Overexpression of the wild-type HFE 
gene in enterocytes and overexpression of the 
iron regulatory peptide hepcidin in the liver are 
other therapeutic approaches that could be inves-
tigated. The HFE genotype may affect the survival 
of patients with myelodysplastic syndrome, and 
studies need to be performed if these patients 
should be treated with potent iron chelation ther-
apy [109]. 
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